On the stock market since 1999, it operates in the world of health and science. It has 7 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 41% a year over the last 4 years. Red columns mark years that ended in a loss.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 13% a year on average.
Sales run at $990K a year. A small number, but proof the product has real buyers.
A loss of $14.3M against $990K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.0001. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 9.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, MCOA sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MCOA is a high-risk stock — not yet profitable, and its future rides on its product catching on.